A multicenter, single-arm, phase II study of single-agent vinflunine in the second-line treatment of patients with gastric cancer
Latest Information Update: 09 Mar 2010
Price :
$35 *
At a glance
- Drugs Vinflunine (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 18 Dec 2007 Status changed from suspended to discontinued.
- 29 Oct 2007 Status changed from recruiting to suspended.
- 07 Nov 2006 New trial record.